These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31242300)

  • 21. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
    Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
    Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia.
    Bashorun AO; Badjie Hydara M; Adigweme I; Umesi A; Danso B; Johnson N; Sambou NA; Fofana S; Kanu FJ; Jeyaseelan V; Verma H; Weldon WC; Oberste MS; Sutter RW; Jeffries D; Wathuo M; Mach O; Clarke E
    Lancet Glob Health; 2022 Feb; 10(2):e257-e268. PubMed ID: 34951974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb.
    Bibby J; Saidu Y; Umesi A; Moneke-Anyanwoke N; Bashorun AO; Hydara MB; Adigweme I; Adetifa JU; Okoye M; Roberts E; Clemens R; Bandyopadhyay AS; Muhammad AK; Mulwa S; Royals M; Jarrahian C; Jeffries D; Kampmann B; Clarke E
    Clin Infect Dis; 2017 Sep; 65(5):851-854. PubMed ID: 28444156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.
    Crothers JW; Ross Colgate E; Cowan KJ; Dickson DM; Walsh M; Carmolli M; Wright PF; Norton EB; Kirkpatrick BD
    Vaccine; 2022 Apr; 40(19):2705-2713. PubMed ID: 35367069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey.
    Trueba G; Jeyaseelan V; Lopez L; Mainou BA; Zhang Y; Whittembury A; Valarezo AJO; Baquero G; de Aguinaga RR; Salinas LJZ; Mancheno MGS; Chacho DEM; Quentin E; Chevez AE; Rey-Benito G; Mach O
    Lancet Reg Health Am; 2022 Jul; 11():None. PubMed ID: 35865654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine.
    Nirmal S; Cherian T; Samuel BU; Rajasingh J; Raghupathy P; John TJ
    Vaccine; 1998; 16(9-10):928-31. PubMed ID: 9682339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.
    Gamage D; Mach O; Ginige S; Weldon WC; Oberste MS; Jeyaseelan V; Sutter RW
    J Infect Dis; 2019 May; 219(12):1887-1892. PubMed ID: 30649505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines.
    Cadorna-Carlos J; Vidor E; Bonnet MC
    Int J Infect Dis; 2012 Feb; 16(2):e110-6. PubMed ID: 22153001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.
    Grassly NC
    J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S439-46. PubMed ID: 24634499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan.
    Bullo UF; Mehraj J; Raza SM; Rasool S; Ansari NN; Shaikh AA; Phul ZA; Memon SA; Baloch RI; Baloch ZA; Chandio SA
    BMC Public Health; 2021 Jan; 21(1):44. PubMed ID: 33407294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.
    Kouiavskaia D; Mirochnitchenko O; Dragunsky E; Kochba E; Levin Y; Troy S; Chumakov K
    J Infect Dis; 2015 May; 211(9):1447-50. PubMed ID: 25391313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protocol for a systematic review and meta-analysis of fractional dose compared with standard dose inactivated polio vaccination in children.
    Mashunye TR; Ndwandwe DE; Dube KR; Shey M; Shelton M; Wiysonge CS
    BMJ Open; 2019 Mar; 9(3):e023308. PubMed ID: 30852530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.
    Troy SB; Kouiavskaia D; Siik J; Kochba E; Beydoun H; Mirochnitchenko O; Levin Y; Khardori N; Chumakov K; Maldonado Y
    J Infect Dis; 2015 Jun; 211(12):1969-76. PubMed ID: 25567841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species.
    Wang Y; Zade J; Moon SS; Weldon W; Pisal SS; Glass RI; Dhere RM; Jiang B
    Vaccine; 2019 Jan; 37(5):698-704. PubMed ID: 30626530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fractional-Dose Inactivated Poliovirus Vaccine Immunization Campaign - Telangana State, India, June 2016.
    Bahl S; Verma H; Bhatnagar P; Haldar P; Satapathy A; Kumar KN; Horton J; Estivariz CF; Anand A; Sutter R
    MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(33):859-63. PubMed ID: 27559683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-sparing effect of Sabin-derived inactivated polio vaccine produced in Japan by intradermal injection device for rats.
    Itoh E; Shimizu S; Ami Y; Iwase Y; Someya Y
    Biologicals; 2023 May; 82():101677. PubMed ID: 37031619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats.
    Ma Y; Ying Z; Li J; Gu Q; Wang X; Cai L; Shi L; Sun M
    Biologicals; 2022 Jan; 75():3-11. PubMed ID: 35058137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.